Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Inventory, Including Noncurrent Portion

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:InventoryIncludingNoncurrentPortion.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's inventory, including noncurrent portion.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's inventory, including noncurrent portion?
BioCryst Pharmaceuticals (BCRX) reported inventory, including noncurrent portion of $34.16M in Q1 2026.
How has BioCryst Pharmaceuticals's inventory, including noncurrent portion changed year-over-year?
BioCryst Pharmaceuticals's inventory, including noncurrent portion increased by 6.9% year-over-year, from $31.97M to $34.16M.
What is the long-term trend for BioCryst Pharmaceuticals's inventory, including noncurrent portion?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's inventory, including noncurrent portion has grown at a 1.2% compound annual growth rate (CAGR), from $28.68M to $29.39M.